News Releases

News Releases

Date Title
Feb 25, 2020 Dr. Thomas Cannell, President and CEO of Sesen Bio, to Host Conference Call to Provide Business Update Highlighting Regulatory Progress and Commercial Opportunity for Vicinium®
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 25, 2020-- Sesen Bio (Nasdaq: SESN ), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced that Dr. Thomas Cannell , President and CEO, will host a conference call on Monday,
Feb 24, 2020 Sesen Bio Announces Changes to the Board of Directors as the Company Advances Toward Commercialization of Vicinium®
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 24, 2020-- Sesen Bio (Nasdaq: SESN ) a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today announced the appointment of Carrie Bourdow , chief executive officer of Trevena, Inc., and
Jan 31, 2020 Sesen Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
CAMBRIDGE, Mass. --(BUSINESS WIRE)--Jan. 31, 2020-- Sesen Bio (Nasdaq: SESN), a late-stage clinical company developing targeted fusion protein therapeutics for the treatment of patients with cancer, today reported that it has granted non-statutory stock options to purchase an aggregate of 85,500
Displaying 11 - 13 of 13
Top